Pfizer to invest $1B in China over next five years — reports
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a new phase of growth. Pfizer China President Jean-Christophe Pointeau said ...
View ArticleNkarta drops another cancer program as it leans into autoimmune disease
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects in autoimmune disease. The biotech will stop investigating NKX019 in...
View ArticleLegend names a president of Carvykti; Novo Nordisk's top North America exec...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the commercial future of the biotech's sole marketed cell therapy, among other...
View ArticleBenevolentAI co-founder returns with plan to save drug developer
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It soared to a $2 billion valuation, pitching a...
View ArticleDaiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode deal
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the...
View ArticleEisai slashes Leqembi sales forecast by almost $100M
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most closely-watched drugs. The company now expects that the Alzheimer's treatment will bring...
View ArticleAmgen and AstraZeneca share positive results in chronic rhinosinusitis
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition....
View ArticleFDA action puts Chinese API manufacturer on import block list
The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer Shandong Boyuan Pharmaceutical Co., whose exports to the US have been blocked...
View ArticleHow Trump, RFK Jr. could influence biopharma; Viking presents weight loss...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleYorvipath’s approval showcases biopharma’s interest in rare endocrine disorder
Michele Rayes used to take 64 pills a day to manage her hypoparathyroidism, a rare endocrine disorder that impairs calcium levels, dampens daily quality of life and can sometimes lead to chronic kidney...
View ArticleThermo Fisher consolidates viral vector work in Massachusetts, cuts 160 workers
Thermo Fisher is closing a factory in Lexington, MA, and merging operations with a newer facility in Plainville, MA, to “optimize” viral vector production, a spokesperson told Endpoints News. The...
View ArticleFDA lifts hold on Novavax vaccines after adverse event reclassified as ALS
The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month after it was first instituted. The vaccine maker
View ArticleRapt cuts immunology program following clinical holds
Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical holds earlier this year. Back in February, the FDA placed holds on two Phase...
View Article23andMe to shut down its therapeutics division
23andMe is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company said Monday evening. The company said it’s exploring all strategic...
View ArticleNeurogene's stock falls in post-market trading after early data in Rett syndrome
Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of the company's gene therapy experienced a serious adverse event,...
View ArticleGSK acquires Parkinson's small molecule from Vesalius
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another undisclosed neurodegenerative condition with Flagship-founded Vesalius...
View ArticleNovartis pays $150M upfront to Schrödinger in new drug deal
Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical drug programs. Founded in 1990, Schrödinger has been developing and selling...
View Article